



Anylam Pharmaceuticals, Inc.
Investor Relations Department
300 Third Street
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: ALNY 1

Last Trade:	67.42
Trade Time:	12:39 PM ET 05.26.2017
Change:	-2.09 (3.000%)
Day Range	67.05 - 70.49
52-Week Range	31.38 - 80.11
Volume	426,922
Market Cap. (\$M)	5,810.499
Shares Out (M)	86.190

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Anylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company's "Anylam 5x15™" product strategy. Anylam's genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 05.24.2017 [Anylam Pharmaceuticals Prices Public Offering of Common Stock](#)
- 05.23.2017 [Anylam Pharmaceuticals Announces Proposed Public Offering of Common Stock](#)
- 05.12.2017 [Anylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer](#)
- 05.10.2017 [Anylam to Webcast Presentations at Upcoming May Investor Conferences](#)
- 05.09.2017 [Anylam Expands Leadership Team with Multiple Experienced Biotech Leaders](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

- 02.15.2017 [Annual Report \(10-K\)](#)
- 03.17.2017 [Definitive Proxy Statement](#)
- 05.05.2017 [Quarterly Report \(10-Q\)](#)
- 11.03.2016 [Quarterly Report \(10-Q\)](#)
- 08.04.2016 [Quarterly Report \(10-Q\)](#)